search results for: MESOBLAST

Flag­ship re­fo­cus­es stealth RNA biotech; Mesoblast en­acts pay cuts for ex­ec­u­tives

Last year
News Briefing

FDA hits Mesoblast with CRL, ask­ing for more adult da­ta in acute graft-ver­sus-host dis­ease

Last year
FDA+

Chemomab changes CEOs, sus­pends mid-stage tri­al; Ex-FDA vac­cine of­fi­cial lends more help to Mesoblast

Last year
Peer Review

Mesoblast’s aGVHD cell ther­a­py will get an­oth­er shot at the FDA

Last year
FDA+

Tonix snaps up as­sets from Healion Bio; Mesoblast gives its BLA an­oth­er shot

Last year
News Briefing

Mesoblast sends in im­proved po­ten­cy as­say, look­ing to re­sub­mit to FDA on acute graft-ver­sus-host dis­ease drug

Last year
R&D
FDA+

For­mer FDA vac­cines deputy Krause heads down un­der as Mesoblast tries again on near­ly en­tire pipeline

3 years ago
People

Mesoblast shares tank af­ter No­var­tis aban­dons a part­ner­ship for the biotech's po­ten­tial Covid-19 treat­ment

3 years ago
Deals
Coronavirus

Mesoblast gets a $110M life­line from Surg­Cen­ter De­vel­op­ment; uniQure still un­sure if gene ther­a­py spurred can­cer ...

4 years ago
News Briefing

Mesoblast spins a PhI­II cell ther­a­py miss in heart fail­ure as a win, high­light­ing pos­i­tive mor­tal­i­ty da­ta

4 years ago
R&D

No­var­tis bags Mesoblast's stem cell ther­a­py for ARDS, in­clud­ing in Covid-19, in a deal worth up to $1.2B+

4 years ago
Deals

FDA gives thumbs down for Mesoblast's aGVHD drug, say­ing one sin­gle-arm tri­al is not enough

4 years ago
Cell/Gene Tx
FDA+

Mesoblast asks for trad­ing halt as PDU­FA date slides by. What's up?

4 years ago
Cell/Gene Tx
FDA+

FDA's ODAC shrugs off ob­jec­tions to Mesoblast's GVHD drug for chil­dren, vot­ing 9-1 in fa­vor and im­prov­ing the odds of ...

5 years ago
FDA+

Aus­tralian cell ther­a­py com­pa­ny Mesoblast joins forces with Ger­many's Grü­nen­thal to tack­le low back pain

5 years ago
Deals
R&D

Stem cell co Mesoblast re­ports PhI­II tri­al suc­cess in chil­dren with GVHD

7 years ago
R&D

Roche's Spark los­es CEO to RNA up­start; Ex-El­e­va­tion On­col­o­gy chief takes over at Af­fimed

Yesterday
Peer Review

Ex­clu­sive: For­mer Genen­tech duo re­unites to push Sono­ma in­to the clin­ic; Ex-Ma­gen­ta com­mer­cial chief heads to Ed­i­tas

11 months ago
Peer Review
1234 Next page Last page

latest

Most read

Ex­clu­sive: In­flu­en­tial De­mo­c­rat will op­pose Biose­cure Act ahead of House vote

14 hours ago
Deals
R&D

No­table shake­ups this week; Re­cur­sion's mixed da­ta; Eli Lil­ly's $1B bet; and more

4 hours ago
Weekly

Fed­er­al judge re­jects phar­ma in­dus­try’s re­quest to halt Mary­land’s 340B law

18 hours ago
Pharma
Law

Non-vi­ral de­liv­ery start­up Vesi­gen Ther­a­peu­tics trims staff as it eval­u­ates 's­trate­gic op­tion­s'

19 hours ago
People
Startups
see latest stream
A service from the Financial Times